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Carotid artery disease-treatment by endarterectomy
and stenting
Abstract
A brief outline of the relevant literature with focus on clinical outcome is
given. With today´s knowledge, CEA(Carotid Endarterectomy) within 3–14
days after symptom onset remains the gold standard of treatment for symp-
tomatic ICA stenosis >50% NASCET.
CAS (Carotid Artery Stenting) may be considered for patients <70 years
of age, patients with restenosis after CEA, after neck radiation and in cases
of difficult anatomy for surgery. After extensive information about the po-
tential risks of the two methods also the patients´s choice has to be consi-
dered.
INTRODUCTION
Worldwide, stroke is the third leading cause of death after ischemicheart disease and cancer (1). Approximately 20% of patients die
within the first year of having stroke and another 30% remains disabled.
The risk of recurrent stroke is highest within the first 30 days. Al-
together, 20% of patients will experience another ischemic event in the
following two years.
An important cause of transient ischemic attack (TIA) and stroke is
atherosclerotic carotid artery stenosis. It accounts for about 20% of cases
of brain infarction and has the highest recurrent stoke risk compared to
all other subtypes of stroke (2, 3). Therefore, rapid intervention in this
patient group is needed and they should be managed efficiently to
minimize the incidence of recurrent stroke.
SYMPTOMS
15% of stroke patients first present with classic TIA symptoms –
slurred speech (dysarthia), limb weakness or numbness, transient mono-
cular blindness (amaurosis fugax), unsteadiness (ataxia) or difficulty
speaking (dysphasia) persisting for less than 24 hours (4). Patients
presenting with TIA and patients with minor or completed stroke
should be examined and screened for carotid stenosis as soon as pos-
sible- at the latest 24–48 hours after onset of symptoms.
DIAGNOSIS
Intraarterial digital subtraction angiography (DSA) is considered as
the classical gold standard for identification and quantification of ca-
rotid artery stenosis. Today, however, non-invasive methods are primarily
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Overview
used: duplex ultrasound (DUS), computed tomography
angiography (CTA) and contrast enhanced magnetic
resonance angiography (CEMRA).
Duplex and transcranial ultrasound examination is
most frequently used in as the baseline screening method
for carotid stenosis in everyday practice. It is less ex-
pensive, reliable and suitable for bedside diagnosis. The
most common sites for significant plaque formation –
the origin of the internal carotid artery (ICA) just above
the bifurcation (around 22 %), can be examined in prac-
tically every patient (5). A recent update of DUS diag-
nostic criteria for carotid stenosis further increases the
accuracy and clinical value of the method (6).
The most cost-effective diagnostic strategy is the use
of DUS and CEMRA in carotid artery stenosis (7). Only
if the DUS is negative and the CEMRA is positive, CTA
or DSA should be performed.
TREATMENT
Patients with symptomatic carotid artery stenosis should
be treated in order to reduce their mostly embolic and in
a lesser degree hemodynamic risk of stroke.
The standard surgical treatment, carotid endarterec-
tomy, has been widely used and is the reference standard
of treatment. Carotid artery angioplasty with stenting is
an alternative method and is currently being used on
selected patients.
CAROTID ENDARTERECTOMY (CEA)
In 1954 the first endarterectomy has been performed
in a patient with symptomatic carotid artery stenosis.
Over the years it evolved and became a routine surgical
treatment for carotid stenosis although adequate clinical
trials to confirm its benefits were lacking.
In 1998, two large randomized controlled trials of
endarterectomy versus medical treatment published their
final results. Although their design was similar, differen-
ces in inclusion and exclusion criteria, methods of deter-
mining degree of stenosis and definitions of outcome
events were present.
Final results of both trials, European Carotid Surgery
Trial (ECST) and North American Symptomatic Caro-
tid Endarterectomy Trial (NASCET), have shown that
CEA, when performed with low surgical morbidity and
mortality, reduces the risk of stroke in patients with high-
-grade carotid stenosis (8, 9). Both studies showed that
approximately 8 patients with more then 70% stenosis
would have to be treated to prevent one ipsilateral stroke
in a five-year period after surgery.
For patients with moderate symptomatic stenosis (50
to 69 percent), NASCET reported greater benefit of end-
arterectomy compared with medically treated patients,
whereas ECST showed no significant benefit. NASCET
showed that 15 patients with 50 to 69% stenosis would
have to be treated to prevent one stroke within five years.
In both trials no significant benefit of endarterectomy
could be demonstrated for patients with symptomatic
carotid stenosis of less then 50 percent. These results
established CEA as the gold standard treatment for the
prevention of a recurrent ischemic event in symptomatic
patients with ipsilateral carotid stenosis greater then 70%
and without a severe neurological deficit with recent
(<180 days) ischemic events and if the center’s peri-
operative strokes and death rate is less then 6%. CEA may
also be performed in symptomatic patients with stenosis
of 50 to 69% free of a severe neurological deficit only if
the perioperative strokes and death rate is less then 3%.
Both studies showed that the benefit of endarterec-
tomy is greater for men then for women, for patients aged
75 and older and for patients with hemispheric symp-
toms. Also, the patients who have had stroke three months
prior to procedure will benefit more from surgery then
those with TIA. Studies suggested that a higher risk of
preoperative ischemic event or death exists in patients
with diabetes, elevated blood pressure, contralateral ca-
rotid occlusion and left-sided disease.
In addition, all treated patients should remain on
antithrombotic therapy before, during and after surgery
and followed-up by the surgeon and the neurologist
(ESO Guidelines, last update 2008; http://www.eso-
stroke.org/pdf/ESO08_Guidelines_English.pdf)
Patients randomized for surgical treatment within 2
weeks after their last ischemic event, benefit more from
surgery (10). However, surgery within 48 hours after
symptom onset may carry a significantly increased mor-
tality and stroke risk compared with surgery 3–14 days
after symptom onset (11.5 vs 3.8%; 11)
PTA WITH STENTING
Carotid angioplasty with stenting is a more recent
endovascular treatment for carotid stenosis. Although it
does not have a long history, it has become an alternative
to CEA. It is a minimally invasive procedure requiring
only a small incision in the groin and local anaesthesia.
A stent is a small tube made of nickel-titanium, a
bendable metal that springs back after being bent, and is
in today’s practice self-expendable after placement. Em-
boli protection devices (EPDs) have also been designed
to protect the brain from embolisation during stenting. It
is used to catch the small particles that may be dislodged
from the plaque into the brain circulation, which may
help reduce the incidence of stroke during the procedure.
The risk of radiation exposure and allergic reaction to
the dye used during the procedure is very low. Stents can
be overgrown by the surrounding tissue and that can
cause restenosis or even occlussion of the vessel, espe-
cially in patients noncompliant to the mandatory life-
long thrombocyte inhibition medication required. The
release of multiple emboli has also been reported during
CAS. Wholey et al. reported the stroke/death rate of 2,
23% when EPD was used. On the other hand, when the
procedure was done without protection, stroke/death oc-
curred in 5,29% of treated patients (12).
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Patients treated with CAS avoid surgical incision on
the neck with the risk of facial nerve injuries and general
anesthesia, and stay shorter in the hospital. This pro-
cedure is also feasible to treat surgically inaccessible sec-
tions of the artery and for treating restenosis after CEA.
To better define the indications for CAS versus CEA
several randomized prospective trials have been designed.
Carotid and Vertebral Artery Transluminal Angioplasty
Study (CAVATAS) showed no difference in major out-
come events between endovascular treatment and ca-
rotid endarterectomy, but 30-day death and stroke rate of
carotid surgery was higher than desirable – 10,0% for
CAS versus 9,9% for CEA (13). This study also reported
that high grade carotid restenosis was more frequent one
year after CAS then after carotid surgery.
The majority of patients treated by the endovascular
approach had, however, PTA alone without stent place-
ment.
In SAPPHIRE (Stenting and Angioplasty with Pro-
tection in Patients at High Risk for Endearterectomy)
study, 334 patients were included (96 symptomatic and
219 asymptomatic) (14). This trial suggested that stent-
ing with protection is not inferior and may be superior to
CEA in terms of a combined end point including stroke,
myocardial infarction and death.
The 3-years follow-up showed similar clinical results
for CAS and CEA (15).
The EVA-3S trial was stopped in November 2005 at
527 patients because of a complication rate of 9.6% for
CAS versus 3.9% for CEA (16).
The SPACE (Stent protected Angioplasty versus Ca-
rotid Endarterectomy; (17),which has recruited 1200 pa-
tients with symptomatic, ³70% ICA stenosis diagnosed
by Duplex ultrasound in Germany, Austria and Switzer-
land reported for the 30 days primary endpoint (ischemic
stroke and/or intracerbral bleeding with symptoms last-
ing >24h) results a rate of 6.84% for carotid artery stent-
ing and 6.34% for carotid endarterectomy.This difference
was not significant. However, non-inferiority of CAS
was not shown. The use of EPD did not reduce compli-
cations.
In the 2-years follow up of this study (18), no signifi-
cant differences were found for clinical endpoints. In the
CAS group, however, a significantly higher (8.9% vs 3.9%)
percentage of -clinically mostly silent-restenoses was ob-
served.
Also in Europe, the ICSS (International Carotid Stent-
ing Study, 19), showed unfavorable outcome measures
(stroke, death or procedural MI) for CAS for the first 120
days after randomization- 8.5% versus 5.2% for the CEA
group(p value 0.006).
A meta-analysis of all 3 European trials (EVA 3S,
SPACE and ICSS; 3433 patients; 18) concluded, that
»stenting for symptomatic carotid stenosis should be avoid-
ed in older patients(age =70 years) but might be as safe
as endarterectomy in younger patients«.
Another meta-analysis (19) including trials up to the
ICSS (but excluding CREST results) concluded, that
»Carotid endarterectomy was found to be superior to
carotid artery stenting for short term outcomes but the
difference was not significant for intermediate term out-
comes; this difference was mainly driven by nondisabling
stroke. Significantly fewer cranial nerve injuries and myo-
cardial infarctions occurred with carotid artery stenting«
In North America, the CREST (Carotid Revasculari-
sation Endarterectomy versus Stent Trial, 21) was conduct-
ed. It's conclusion was, that-at 4 years- »among patients
with symptomatic or asymptomatic carotid stenosis, the
risk of the composite primary outcome of stroke, myo-
cardial infarction or death did not differ significantly in
the group undergoing carotid-artery stenting and the
group undergoing endarterectomy« (CAS 7,2% vs CEA
6.8%, n.s.).
»During the periprocedural period, there was a higher
risk of stroke with stenting and a higher risk of myo-
cardial infarction with endarterectomy«
A recent analysis of the CREST data concerning res-
tenosis at 2 years showed no significant difference- CAS
6.0% vs CEA 6.3% (23).
CONCLUSION
CEA remains the gold standard of treatment for symp-
tomatic ICA stenosis >50% NASCET.
CAS may be considered for patients <70 years of age,
patients with restenosis after CEA, after neck radiation
and in cases of difficult anatomy for surgery. After exten-
sive information about the potential risks of the two
methods also the patients's choice has to be considered.
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